Carl Balog, MD
Interventional Pain Medicine · Portland, ORNPI 1447287636
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 620 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,348 and has fallen 75.3% since, to $827 in 2025.
Across 620 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$793
- Collegium Pharmaceutical, Inc.$678
- Relievant Medsystems, Inc.$620
- Biotronik NRO, Inc.$584
- plus $6K from 44 others
Across 7 payments — averaging $7078.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mesoblast, Inc.$47K
- Surgalign Spine Technologies, Inc.$2K
What the payments were for
- Travel & lodging$2682%
- Food & beverage$11,49997%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$580
- XEOMIN$300
- ASCLERA$300
- Ryoncil$178
- INTELLIS$175
- Proclaim Family of SCS IPGs$144
- Prospera$133
- BOTOX$125
- Tymlos$125
- NURTEC ODT$121
- GENERAL - THERAPIES$121
- SlMMETRY$109
- AIMOVIG$106
How this compares
$11,797 in reported general payments places this provider in the 65th percentile of 22 interventional pain medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 13 | $14,083 |
| Emgality PenGalcanezumab-Gnlm | 15 | $10,160 |
| Oxycodone Hcl | 334 | $9,205 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 52 | $7,453 |
| Fentanyl | 30 | $5,840 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 171 | $5,682 |
| Buprenorphine Hcl | 93 | $4,347 |
| Morphine Sulfate ErMorphine Sulfate | 127 | $4,218 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 38 | $1,509 |
| Pregabalin | 83 | $1,410 |
| Morphine Sulfate | 37 | $1,270 |
| Naloxone Hcl | 12 | $848 |
| Duloxetine Hcl | 101 | $808 |
| Baclofen | 63 | $688 |
| Methadone Hcl | 43 | $661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Upsher-smith Laboratories LLCTopiramate | $295 | $12714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 22 interventional pain medicine providers in Oregon.
Other interventional pain medicine in Portland
- Vladimir FiksPortland$8K
- Navnit Kaur-JayaramPortland$654
- Gregory MooreEugene$377K
- Gregory PhillipsEugene$50K
- Stephen PeirceEugene$28K
- Rishi VoraEugene$16K
- George JohnstonMedford$14K
- Poly ChenSalem$14K
- Kwo Wei HoTigard$13K
- Joseph DunnEugene$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.